MX2009013575A - Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa. - Google Patents

Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.

Info

Publication number
MX2009013575A
MX2009013575A MX2009013575A MX2009013575A MX2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A MX 2009013575 A MX2009013575 A MX 2009013575A
Authority
MX
Mexico
Prior art keywords
fti
sensitivity
hh2ax
biomarker
histone h2ax
Prior art date
Application number
MX2009013575A
Other languages
English (en)
Inventor
Andrea Dawn Basso-Porcaro
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009013575A publication Critical patent/MX2009013575A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere por ejemplo, a métodos para predecir sensibilidad celular a inhibidores de farnesil proteína transferasa.
MX2009013575A 2007-06-12 2008-06-11 Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa. MX2009013575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94335307P 2007-06-12 2007-06-12
PCT/US2008/007294 WO2008156613A1 (en) 2007-06-12 2008-06-11 Histone h2ax (hh2ax) biomarker for fti sensitivity

Publications (1)

Publication Number Publication Date
MX2009013575A true MX2009013575A (es) 2010-07-02

Family

ID=39764863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013575A MX2009013575A (es) 2007-06-12 2008-06-11 Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.

Country Status (6)

Country Link
US (1) US20110009387A1 (es)
EP (1) EP2171447A1 (es)
JP (1) JP2010529479A (es)
CA (1) CA2690556A1 (es)
MX (1) MX2009013575A (es)
WO (1) WO2008156613A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
WO2016126616A1 (en) 2015-02-02 2016-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax
MX2017013802A (es) 2015-04-29 2018-08-15 Radius Pharmaceuticals Inc Métodos para tratar el cáncer.
CA3036568A1 (en) * 2016-09-27 2018-04-05 Radius Health, Inc. Methods for treating ovarian cancer
MX2019007748A (es) 2017-01-05 2019-09-09 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222590T2 (de) * 2001-10-30 2008-06-19 Ortho-Clinical Diagnostics, Inc. Methoden zur feststellung von akute myeloischen leukämie
AU2004202980B2 (en) * 2003-07-01 2009-05-07 Veridex, Llc Methods for assessing and treating leukemia
WO2006042035A2 (en) * 2004-10-07 2006-04-20 Pharmacyclics, Inc. Method of monitoring anti-tumor activity of an hdac inhibitor

Also Published As

Publication number Publication date
CA2690556A1 (en) 2008-12-24
JP2010529479A (ja) 2010-08-26
US20110009387A1 (en) 2011-01-13
WO2008156613A1 (en) 2008-12-24
EP2171447A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
MX2009013575A (es) Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.
WO2011163423A3 (en) Methods and compositions for cell permeable stat3 inhibitor
EA200802285A1 (ru) Бивалентные миметики smac и их применения
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
CY1118012T1 (el) Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
WO2008128171A3 (en) Diazo bicyclic smac mimetics and the uses thereof
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
CL2015001124A1 (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de kinasa p13
MX2010003328A (es) Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas.
WO2012096545A3 (ko) 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
TN2012000485A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
WO2012178208A3 (en) Selective inhibitors of histone deacetylase isoform 6 and methods thereof
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
Naarmann et al. mRNA silencing in human erythroid cell maturation: heterogeneous nuclear ribonucleoprotein K controls the expression of its regulator c-Src
EA201070179A1 (ru) Антиген, связанный с вариантами рака легкого и лимфомами
WO2012128577A3 (ko) 패혈증 단백질 치료제의 효능 분석 및 스크리닝 방법
WO2006055880A3 (en) Diagnostic pkm2 methods and compositions
Pouliquen et al. Biomarkers of tumor invasiveness in proteomics
EP1899463A4 (en) BIOMARKERS FOR EVALUATING THE PROBABILITY THAT A TUMOR IS SENSITIVE TO A MTOR INHIBITOR
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
WO2009126947A3 (en) Heteroaryl-substituted bicyclic smac mimetics and the uses thereof